NGL Fine-Chem Limited is a publicly listed pharmaceutical manufacturing company headquartered in Mumbai, India, specializing in the production of Active Pharmaceutical Ingredients (APIs), intermediates, and finished dosage forms primarily for the veterinary and human healthcare segments. Established in 1981, the company has carved a niche in the animal health API sector globally and has earned a reputation for product quality, regulatory compliance, and technical competence.
Core Business and Product Portfolio
NGL Fine-Chem operates across four major product categories:
-
APIs for Animal Health:
- Homidium Chloride
- Nitroxynil
- Clorsulon
- Parvaquone
- Buparvaquone
- Isometamidium Chloride Hydrochloride
- Toldimfos Sodium
- Butaphosphan
- Imidocarb Dipropionate
- Triclabendazole
- Rafoxanide
- Diminazene Aceturate
- S-Methoprene
- Carprofen
-
APIs for Human Health:
-
Intermediates and Specialty Chemicals:
- 1,4,7-Trimethyl-1,4,7-Triazacylononane
- N-Ethyl Glucamine
-
Finished Dosage Forms (Veterinary):
- Diminazene Aceturate Granules
- Homidium Chloride Tablets
The company supplies these APIs and finished products to pharmaceutical formulation companies and veterinary medicine brands across over 50 countries.
Specialization and Unique Selling Proposition (USP)
NGL Fine-Chem is globally recognized for its specialization in veterinary APIs, particularly anti-protozoal and anti-parasitic agents. Its unique strengths include:
- End-to-end production capabilities from intermediates to APIs and finished formulations
- Strong R&D capabilities for developing complex veterinary actives
- Backward integration to ensure cost control and supply consistency
- Broad registration footprint in regulated and semi-regulated markets
The company’s ability to meet stringent regulatory and pharmacopoeial standards (BP, EP, USP, IP) positions it as a reliable API source for global veterinary drug manufacturers.
Certifications and Quality Compliance
NGL Fine-Chem’s manufacturing facilities adhere to international quality and regulatory norms. The company holds:
- WHO-GMP certification
- ISO 9001:2015 certification
- Audits and approvals by various international regulatory authorities including ANVISA (Brazil) and GCC Health Ministries
All products undergo multi-stage quality testing including in-house and third-party laboratories, with comprehensive documentation support including DMFs, CoAs, and stability data.
Export and Shipment Records
NGL Fine-Chem exports to a wide geographic footprint across Latin America, Asia, Africa, and the Middle East. Based on trade data and financial reporting:
- The company exports to over 50 countries
- Over 60% of its revenue comes from international markets
- Top markets include Brazil, Egypt, Mexico, Vietnam, and South Africa
- Annual export shipments exceed 500 MT of APIs and intermediates
- Registered products in over 30 countries, especially in Latin America and Asia
Its long-term contracts and distribution partnerships ensure a stable recurring revenue stream from key customers abroad.
Financial and Operational Capabilities
NGL Fine-Chem is a financially sound organization with consistent revenue and profit growth. As per its latest annual report:
- Revenue (FY 2023): INR 301 crore (~USD 36 million)
- Net Profit (FY 2023): INR 33 crore (~USD 4 million)
- EBITDA Margin: 17–18%
- Market Capitalization: INR 500+ crore (~USD 60 million)
The company operates two manufacturing sites, one in Tarapur and one in Navi Mumbai, both equipped with reactors, cleanrooms, analytical labs, and R&D units. Expansion projects are underway to boost production capacity and add new product lines.
Target Market and Industry Positioning
NGL Fine-Chem serves global pharmaceutical companies, veterinary healthcare firms, and contract manufacturing organizations (CMOs). It positions itself as:
- A cost-effective alternative to Western API manufacturers
- A niche product supplier in the underserved animal health sector
- A strategic partner for companies looking to outsource complex synthesis and API manufacturing
Its integrated operations, regulatory strength, and niche product focus give it an edge in the highly competitive API landscape.
Recognitions and Industry Engagement
NGL Fine-Chem is a recognized entity in the Indian pharmaceutical export ecosystem:
- Member of Pharmexcil (Pharmaceutical Export Promotion Council of India)
- Regular participant in CPhI Worldwide, VIV Asia, and IPPE
- Featured in industry reports for its leadership in veterinary APIs
- Collaborates with Indian Drug Manufacturers’ Association (IDMA) and Indian Veterinary Association for compliance and innovation
The company is steadily expanding its formulation business while maintaining leadership in select API segments, reinforcing its vision to be a global player in animal and human health chemistry.
NGL Fine-Chem Limited continues to build value through science, compliance, and long-term partnerships, offering a stable and trustworthy platform for pharmaceutical companies around the world.
